InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (2 ops.)
Insider track record
CFODisclosed buys
1
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the complete record of transactions filed by Shah Preetam, Chief Financial Officer. Director active across 2 companies, notably Cidara Therapeutics, Inc.. In total, 8 reports have been published. Split: 1 buy · 2 sells. Total volume traded: €48k. History available since 12 November 2021. The latest transaction was filed on 2 February 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Shah Preetam
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
24,000 shares0Common StockSEC:0001601485-26-000008:0
108,750 shares0Common StockSEC:0001610618-24-000026:0
18,931 shares@ US$0.669815.5% of flowCommon StockSEC:0001610618-24-000009:0
90,000 shares0Common StockSEC:0001610618-23-000028:0
6,648 shares@ US$1.5312.7% of flowCommon StockSEC:0001610618-23-000011:0
50,000 shares0Common StockSEC:0001610618-22-000081:0
51,250 shares0Common StockSEC:0001610618-22-000029:0
20,000 shares@ US$1.5456.0% of flowCommon StockSEC:0001610618-21-000106:0
Canonical exit: 10 Feb 2022 (T+90)
8 of 8 declarations
About Shah Preetam
Shah Preetam is Directeur Financier & Responsable Commercial at Cidara Therapeutics, Inc. (CFO & CBO) and is also listed at Elicio Therapeutics, Inc. (See Remarks). He has 8 filings in total, and across the sampled recent filings from 2021-11-15 to 2026-02-03, the amounts shown are EUR 26898 of buys and EUR 21108 of sells.
